A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks

Primary Objective • To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks among patients treated with Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg once daily. Secondary Objectives * To assess the improvement in reflux symptoms using the GERD-Q score at 8 weeks. * To evaluate the incidence of adverse events across treatment groups.

NCT Number	NCT06953986
Lead Sponsor	Asian Institute of Gastroenterology, India
Conditions	GERD
Enrollment	414 participants
Start Date	2025-12-20
Primary Completion	2026-11-20 (estimated)
Study Completion	2027-12-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-06